Patient and Allograft Survival. A, Patient survival was similar among all groups over mean (SD) posttransplant patient follow-up of 6.8 (2.2) years in the eculizumab group, 8.7 (3.2) years in the +XM control group, and 8.3 (2.3) years in the age-matched −XM group. B and C, Overall and death-censored allograft survival was similar in the +XM groups, but both were reduced as compared with the −XM group over mean (SD) posttransplant follow-up of 6.3 (2.5) years, 7.6 (3.5), and 7.9 (2.5) years in the eculizumab, +XM control, and −XM control groups, respectively. EC indicates eculizumab; −XM, negative crossmatch; +XM, positive crossmatch.